▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3809 by analyst upside · 2026-09-28
GILD
Gilead Sciences, Inc.
Healthcare · Market Cap $187B · P/E 0x
ANALYST PRICE TARGET
+5.1%
implied upside to consensus target
Current Price $150.93
Consensus Target $158.65
Bull Target $180.0
Bear Target $123.0
Analysts Covering 26
ANALYST CONSENSUS - BUY
Strong Buy
6
Buy
14
Hold
5
Sell
1
52-Week Low $108.46
52-Week High $157.29
YTD Return +26.4%
FUNDAMENTALS
Market Cap $187B
P/E Ratio (TTM) N/A
Forward P/E 15.3x
EPS (TTM) $-2.66
PEG Ratio 2.24
Dividend Yield 2.17%
Revenue (TTM) $30.5B
Profit Margin -10.6%
52-WEEK RANGE
52-Week Low $108.46
52-Week High $157.29
Current Price $150.93
Bear Target $123.0
Bull Target $180.0
● Now $150.93 ● Target $158.65
TRADING DATA
Avg Volume 6.4M
YTD Return +26.4%
Analyst Count 26
Consensus Buy
Upside to Target +5.1%
Last Updated 2026-09-28

ANALYST SUMMARY

Gilead Sciences, Inc. (GILD) is currently trading at $150.93 with a Wall Street consensus price target of $158.65, implying potential upside of 5.1% over the next 12 months. 26 analysts currently cover GILD, with a consensus rating of Buy - 77% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $180.0, while the most cautious has a target of $123.0.

GILD operates in the Healthcare sector with a market capitalisation of $187B. The stock is up 26.4% year-to-date and is currently trading near the upper end of its 52-week range of $108.46 – $157.29.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

AMGN -6.1%
Amgen Inc.
$224B · P/E 25.8x · Hold
ABT +18.7%
Abbott Laboratories
$175B · P/E 32.8x · Buy
VRTX +8.4%
Vertex Pharmaceuticals Incorporated
$133B · P/E 30.7x · Buy
MDT +18.3%
Medtronic plc
$113B · P/E 21.8x · Buy
TMO -3.2%
Thermo Fisher Scientific Inc.
$250B · P/E 36.4x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for GILD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HSBC - Reiterated
Buy → Buy 2026-09-10 Building track record
RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-08-05 Building track record
Cantor Fitzgerald reit
Overweight → Overweight 2026-08-05 40% win rate (10 calls)
Needham reit
Buy → Buy 2026-08-05 20% win rate (5 calls)
Barclays - Reiterated
Equal-Weight → Equal-Weight 2026-07-29 Building track record
Morgan Stanley - Reiterated
Overweight → Overweight 2026-07-27 Building track record
Leerink Partners ↓ Downgrade
Outperform → Market Perform 2026-07-21 29% win rate (7 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-07-08 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
61
out of 100
Coverage depth
25/30
Consensus clarity
22/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →